Mircera approved for anemia in pediatric patients with CKD

Print Friendly, PDF & Email


Red blood cells
Mircera®, methoxy polyethylene glycol-epoetin beta, was approved by the US Food and Drug Administration (FDA) to treat anemia in pediatric patients who have chronic kidney disease (CKD). The drug is indicated for patients ages 5 to 17 years on hemodialysis who are switching from another erythropoiesis-stimulating agent (ESA) after their hemoglobin levels... [Read Article]
Print Friendly, PDF & Email

Dasatinib outcomes similar to imatinib in pediatric Ph+ ALL

Print Friendly, PDF & Email


Child with leukemia
Photo by Bill Branson
Dasatinib used during induction and consolidation in the Children’s Oncology Group (COG) AALL0622 trial provided early response rates for children with Ph-positive (Ph+) acute lymphoblastic leukemia (ALL), according to investigators. But the early response rates did not improve event-free survival (EFS) compared to the use of consolidation... [Read Article]
Print Friendly, PDF & Email

VF incidence increases significantly in kids after ALL treatment

Print Friendly, PDF & Email


Lumbar vertebrae (shown in red)
Credit: Anatomography
A 6-year prospective study from the Canadian STOPP investigators revealed that following treatment for acute lymphoblastic leukemia (ALL), approximately 1 out of 3 children experiences vertebral fractures (VF) and 1 out of 5 children shows non-VF. Glucocorticoid use and vertebral fractures at diagnosis emerged as significant... [Read Article]
Print Friendly, PDF & Email

Early infection could prevent ALL, doc says

Print Friendly, PDF & Email


Smiling baby
Photo by Petr Kratochvil
Childhood acute lymphoblastic leukemia (ALL) may be preventable, according to a researcher. Mel Greaves, PhD, of The Institute of Cancer Research in London, UK, has reviewed more than 30 years of research and concluded that ALL develops in 2 steps—genetic mutation before birth and further genetic change... [Read Article]
Print Friendly, PDF & Email

Regimen can improve DFS in newly diagnosed T-ALL

Print Friendly, PDF & Email


Vials of drugs
Photo by Bill Branson
The addition of nelarabine can improve treatment outcomes for certain patients with T-cell acute lymphoblastic leukemia (T-ALL), according to a phase 3 trial. Patients with newly diagnosed, intermediate- or high-risk T-ALL had a significant improvement in 4-year disease-free survival (DFS) if they received nelarabine in addition to chemotherapy... [Read Article]
Print Friendly, PDF & Email

MSC product can treat refractory GVHD

Print Friendly, PDF & Email


Mesenchymal stem cells
Results from a phase 3 trial suggest a mesenchymal stem cell (MSC) product can treat steroid-refractory, acute graft-versus-host disease (GVHD) in children. The product, remestemcel-L (MSC-100-IV), produced an overall response rate of 69% at day 28, with complete resolution of GVHD in 29% of patients. Adverse events (AEs) in this trial... [Read Article]
Print Friendly, PDF & Email

CHMP backs approval of dasatinib for kids

Print Friendly, PDF & Email


CML cells
Image by Difu Wu
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended changes to the marketing authorization for dasatinib (Sprycel). The CHMP is recommending approval for dasatinib as a treatment for pediatric patients with newly diagnosed, Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase... [Read Article]
Print Friendly, PDF & Email

Team maps genetic evolution of T-ALL subtype

Print Friendly, PDF & Email


Bone marrow smear of T-ALL
© Hind Medyouf, German
Cancer Research Center
Single-cell analysis has revealed key genetic events in a type of T-cell acute lymphoblastic leukemia (T-ALL), according to researchers. The team tracked the branching pattern of evolution in STIL-TAL1-positive T-ALL and identified mutations that may trigger development of the disease. The researchers believe... [Read Article]
Print Friendly, PDF & Email

Drug nets orphan designation for SCD

Print Friendly, PDF & Email


A sickled red blood cell
beside a normal one
Image by Betty Pace
The European Commission (EC) has granted orphan designation to Altemia (formerly SC411) for the treatment of pediatric patients with sickle cell disease (SCD). Altemia gelatin capsules are designed to replenish the lipids destroyed by sickle hemoglobin. Altemia is intended to be... [Read Article]
Print Friendly, PDF & Email